{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:09Z","timestamp":1791849369903,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clml.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:42:47Z","timestamp":1724395367000},"page":"e71-e81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina Nicoleta","family":"Badelita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-9653","authenticated-orcid":false,"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Spanoudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guldane Cengiz","family":"Seval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-7253","authenticated-orcid":false,"given":"Zorica","family":"Cvetkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selami Ko\u00e7ak","family":"Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Dalampira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Bezirgiannidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pirsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Valkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Ursuleac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Sretenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Sevastoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josip","family":"Batinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinziana","family":"Barbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2024.08.007_bib0001","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.clml.2024.08.007_bib0002","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2024.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.08.007_bib0004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2024.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosinol","year":"2019","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.clml.2024.08.007_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2024.08.007_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2024.08.007_bib0008","first-page":"83","article-title":"Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation","volume":"28","author":"Sidana","year":"2022","journal-title":"Trans Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2024.08.007_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jtct.2022.03.020","article-title":"Impact of induction with VCD versus VRD on the outcome of patients with multiple myeloma after an autologous hematopoietic stem cell transplantation","volume":"28","author":"Afrough","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.08.007_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ejh.13280","article-title":"Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma","volume":"103","author":"Uttervall","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.007_bib0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2016.214","article-title":"The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents","volume":"52","author":"Chakraborty","year":"2017","journal-title":"Bone Mar Trans"},{"issue":"10","key":"10.1016\/j.clml.2024.08.007_bib0012","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.clml.2019.09.597","article-title":"VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: a phase III, randomized study","volume":"19","author":"Kumar","year":"2019","journal-title":"Clin Lymph, Myeloma Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2024.08.007_bib0013","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.08.007_bib0014","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.007_bib0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2024.08.007_bib0016","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.clml.2024.08.007_bib0017","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.007_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.08.007_bib0019","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.08.007_bib0020","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.08.007_bib0021","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.clml.2024.08.007_bib0022","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.08.007_bib0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.007_bib0024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024003124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024003124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:20Z","timestamp":1738061960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2152265024003124"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}